| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B655799-1ml |
1ml |
期货  |
|
| 规格或纯度 | 10mM in DMSO |
|---|---|
| 英文名称 | BMS-309403 sodium |
| 生化机理 | BMS-309403 钠是一种强效、口服活性和选择性脂肪细胞脂肪酸结合蛋白（又称 FABP4、aP2）抑制剂，对 FABP4、FABP3 和 FABP5 的 K i s 分别小于 2、250 和 350 nM。BMS-309403 钠能与脂肪-蛋白质相互作用。 |
| 储存温度 | 干燥,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with K i s of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells . In Vitro Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BMS-309403 sodium (15 mg/kg; chronic treatment; daily for 6 weeks) improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but did not affect endothelium-independent relaxations. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6J mice (ApoE −/− mice)Dosage: 15 mg/kg Administration: Chronic treatment ; daily for 6 weeks Result: Significantly increased the phosphorylated eNOS (Ser1177) and total eNOS but not the phosphorylated to total eNOS ratio in aortae of 18 weeks old ApoE −/− mice. |
| 分子量 | 496.53 |
|---|
首页
400-620-6333
